Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer | Zendy

Rashmi K. Murthy | Zendy; Sherene Loi | Zendy; Alicia Okines | Zendy; Elisavet Paplomata | Zendy; Erika Hamilton | Zendy; Sara A. Hurvitz | Zendy; Nancy U. Lin | Zendy; Virginia F. Borges | Zendy; Vandana G. Abramson | Zendy; Carey K. Anders | Zendy; Philippe L. Bédard | Zendy; Mafalda Oliveira | Zendy; Erik Jakobsen | Zendy; Thomas Bachelot | Zendy; Shlomit Strulov Shachar | Zendy; Volkmar Müller | Zendy; Sofía Braga | Zendy; François P. Duhoux | Zendy; Richard Greil | Zendy; David Cameron | Zendy; Lisa A. Carey | Zendy; Giuseppe Curigliano | Zendy; Karen A. Gelmon | Zendy; Gabriel N. Hortobágyi | Zendy; Ian E. Krop | Zendy; Sibylle Loibl | Zendy; Mark D. Pegram | Zendy; Dennis J. Slamon | Zendy; Maria Corinna Palanca-Wessels | Zendy; Luke Walker | Zendy; Wentao Feng | Zendy; Eric P. Winer | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer

Author(s) -

Rashmi K. Murthy,

Sherene Loi,

Alicia Okines,

Elisavet Paplomata,

Erika Hamilton,

Sara A. Hurvitz,

Nancy U. Lin,

Virginia F. Borges,

Vandana G. Abramson,

Carey K. Anders,

Philippe L. Bédard,

Mafalda Oliveira,

Erik Jakobsen,

Thomas Bachelot,

Shlomit Strulov Shachar,

Volkmar Müller,

Sofía Braga,

François P. Duhoux,

Richard Greil,

David Cameron,

Lisa A. Carey,

Giuseppe Curigliano,

Karen A. Gelmon,

Gabriel N. Hortobágyi,

Ian E. Krop,

Sibylle Loibl,

Mark D. Pegram,

Dennis J. Slamon,

Maria Corinna Palanca-Wessels,

Luke Walker,

Wentao Feng,

Eric P. Winer

Publication year - 2019

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1914609

Subject(s) - capecitabine , trastuzumab , metastatic breast cancer , oncology , medicine , breast cancer , cancer , colorectal cancer

Patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer who have disease progression after therapy with multiple HER2-targeted agents have limited treatment options. Tucatinib is an investigational, oral, highly selective inhibitor of the HER2 tyrosine kinase.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research